New standard: Durvalumab recommended for LD-SCLC in S3 guideline

Since its update in April 2025, the German S3 guideline for lung cancer has recommended the checkpoint inhibitor durvalumab as consolidative therapy for all patients with LD-SCLC without progression after radiochemotherapy (RCT) [1]. With this recommendation—a direct guideline implementation of the results of the ADRIATIC study published in September 2024 [2]—immunotherapy with durvalumab is currently the only approved immunotherapy for the entire SCLC spectrum [3].